The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Research Identifies Genetic Variants that Might Predispose Pregnant Women to Rare Heart Condition
April 21st 2021An analysis of more than 400 women with peripartum cardiomyopathy is providing insight into a group of genetic variants that could help identify patients who are genetically predisposed to the rare cardiovascular condition.
Delaying, Cancelling Surgeries Has Taken Toll on Patients with Cardiovascular Conditions
April 21st 2021Data from phone interviews indicate patients who had cardiovascular surgeries delayed or cancelled as a result of the COVID-19 pandemic may have experienced additional psychological stress as a result.
Aspirin Without an Indication Comes with More Risk than Reward in Patients on DOACs
April 20th 2021Data from a group of anticoagulant clinics in Michigan suggests aspirin use without an indication in patients with atrial fibrillation or VTE using DOACs was associated with an increased risk of bleeding and hospitalizations.
ACC/AHA 2017 Exercise Recommendations May Not Be Enough to Prevent Hypertension
April 19th 2021An analysis of the CARDIA study by investigators at UCSF suggests a recommendation of 5 hours of physical activity per week may be more appropriate than the current ACC/AHA recommendation for reducing the risk of hypertension.
Dapagliflozin Effective for Reducing CV Risk in Diabetes, Irrespective of Kidney Function
April 16th 2021TIMI Group investigators found the effects of dapagliflozin on cardiovascular risk in patients with diabetes were comparable in those with markers of CKD and those without markers of CKD at baseline.
Inadequate Response to Arthritis Therapy Could Signal Increased Risk of Heart Attack
April 16th 2021An analysis of medical data from a major database in Taiwan suggests an inadequate response to DMARD therapy among patients with rheumatoid arthritis was associated with increased risk of acute coronary syndrome.
Race, Gender, & Income Influence Access to SGLT2 Inhibitors Among US Patients
April 15th 2021Using data from nearly 1 million patients with type 2 diabetes in a commercial database, investigators provide a comprehensive of the impact race/ethnicity, gender, and income can have on the likelihood of receiving a prescription for SGLT2 inhibitors.
Low-Intensity Walking Program Fails to Show Benefit for Peripheral Artery Disease
April 14th 2021A trial led by clinicians from Northwestern Medicine suggests the presence of ischemic leg symptoms could serve as a useful indicator for patients to help determine whether they will see a meaningful benefit from their walking program.
CLARIFY: Diabetes Poses Major Risk in Patients with Coronary Syndromes
April 13th 2021An analysis of the CLARIFY registry is providing clinicians with further insight into the impact of diabetes in patients with chronic coronary syndromes, particularly the increased risk of stroke, myocardial infarction, and cardiovascular death.